Biomatlante’s MBCP Matrix Selected for Fracture Study

MBCP+™, Biomatlante's synthetic bone graft matrix, has been confirmed as the adapted matrix of choice for tissue engineering and was selected for use in a 5-year trial in the treatment of long bone nonunions.

The ORTHOUNION randomized clinical trial will compare a combination of MBCP+ and expanded bone marrow mesenchymal stem cells (MSCs) to...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us